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Abstract
Background: Amajor problem in identifying the best therapeutic targets for cancer is the molecular heterogeneity of
the disease. Cancer is often caused by an accumulation of mutations which produce irreversible damage to the cell’s
control mechanisms of survival and proliferation. Different mutations may affect these cellular anachronisms through
a combination of molecular interactions which may be dynamically changing during cancer progression. It has been
previously shown that cancer accumulates mutations over time. In this paper we address the problem of cancer
heterogeneity by modeling cancer progression using somatic mutation and gene expression cross-sectional data.
Results: We propose a novel formulation of integrating somatic mutation and gene expression data to infer the
temporal sequence of events from cross-sectional data. Using a mixed integer linear program we model the
interaction between groups of different mutated genes and the resulting modifications at the gene expression level.
Our approach identifies a partition of mutation events which gradually produce gene expression changes to a
partition of genes over time. The proposed formulation is tested using both simulated data and real breast cancer
data with matched somatic mutations and gene expression measurements from The Cancer Genome Atlas. First, we
classify the genes as oncogenes or tumor suppressors based on the frequency of driver mutations. As expected, the
most frequently mutated genes in breast cancer are PIK3CA and TP53 genes. Then, we select those genes with most
frequent driver mutations and a set of genes known to play roles in cancer development. Furthermore, we apply the
proposed mixed integer linear program to identify the temporal order in which genes mutate and, simultaneously,
the changes they produce at the gene expression level during cancer progression. In addition, we are able to identify
known causal relationships between mutations and gene expression changes in PI3K/AKT and TP53 pathways.
Conclusions: This paper proposes a new model to infer the temporal sequence in which mutations occur and lead
to changes at the gene expression level during cancer progression. The approach is general and can be applied to any
data sets with available somatic mutations and gene expression measurements.
Keywords: Cancer progression, Somatic mutation, Gene expression, Mixed integer linear program, Breast cancer
Background
Existing methods for identifying cancer specific markers
and therapeutic targets typically analyze genetic, tran-
scriptomics, proteomics or epigenetic data in search
of common patterns. One of the biggest challenges in
biomarker discovery is the heterogeneity of cancer data.
Specific patterns discovered in one study often fail to
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validate in other studies or different data sets. The hetero-
geneity observed in clinical data may be due to (i) limi-
tations associated with the platforms used for generating
molecular data (e.g., sequencing, microarray, etc.), since
batch effects are commonly observed between different
platforms or protocols; (ii) limitations associated with
existing cancer data sets, which are currently predomi-
nantely cross-sectional. This means that one time point
measurements are generated for all patients, although
suchmeasurementsmay not necessarily be themost infor-
mative ones. In fact, certain genes dynamically change
expression levels during the cell cycle, so that one time
point measurements of gene expression may not cap-
ture the steady state expression level; (iii) imperfections
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of clinical diagnosis and the ensuing difficulty in assess-
ing the stage of each patient’s tumor. As a result, clini-
cal samples may not always be properly annotated; (iv)
the reduced sample size with respect to the large num-
ber of measured features (genes or other molecules),
which decreases the statistical power of the majority
of commonly used approaches for biomarker discovery
and patient stratification; (v) the heterogeneity of cancer
mechanisms, which may also dynamically change during
cancer progression.
In light of this, much of the research currently
undertaken using cross-sectional data aims at deter-
mining whether the order in which genetic alterations
occur within tumors follows common progression paths.
Although not all patients with the same type of can-
cer harbor the exact same set of genetic abnormalities,
there seems to be at least a subset of such changes that
are consistent across a set of patients. This suggests that
several combinations of mutations and gene expression
patterns may lead to similar changes in cancer initiation
and progression mechanisms such as apoptosis, differ-
entiation, migration, and proliferation. In other words,
different molecular patterns may contribute to cancer
growth and proliferation in a similar way, i.e., through the
deregulation of similar cellular mechanisms.
Much effort has recently been undertaken to collect,
organize and make publicly available multiple data types
obtained from genetic analysis of tumor samples. A case
in point is the research developed by the The Cancer
Genome Atlas (TCGA) Network, whereby different types
of cancer have been profiled, such as breast invasive
carcinoma [1], lung adenocarcinoma [2], lung squamous
carcinoma [3], colon cancer [4], among others.
Existing data sets of cross-sectional data have been
extensively used to derive temporal models capable
of inferring sequences of mutational events and/or
sequences of affected pathways responsible for driving
cancer progression. In [5], Bayesian networks constructed
using mutation data were used to infer the temporal order
of genetic mutations. The concept of probability rais-
ing was applied to copy number variation (CNV) data
to infer causal models of cancer progression in [6] . The
model derived in [7] provided a quantitative understand-
ing of the dynamics of tumorigenesis with respect to
mutation, selection, genetic instability, and tissue archi-
tecture. The authors in [8] developed a model of somatic
evolution of colorectal cancer based on published data
and used it to investigate the effect of different param-
eters on tumor evolution on a global scale, while those
in [9] suggested that stochastic dynamics alone might be
responsible for either remission or rapid growth of tumors
in the hematopoietic system.
The importance of connecting different types of
genomic alterations (as opposed to a single type of
genomic data) was recognized in [10] and [11], where
probabilistic inference was used to predict the degree to
which the activity of a pathway was altered in a given
patient. For this purpose, each gene was modeled as a
set of interconnected variables associated with expres-
sion, CNV and protein levels, and a priori information of
molecular pathways was used to define the gene groups of
interest and model the gene interactions.
Additional studies [12–14] have established a correla-
tion between certain mutations and survival rates, thus
revealing the genetic heterogeneity of cancer and the
existence of multiple subtypes. Another example is the
prognostic role of BRCA1mutation in patients with triple-
negative breast cancer [15].
Thus far, most attempts at reconstructing tumor pro-
gression at the pathway level have considered only known,
a priori defined, pathways. The problem of simultaneously
inferring the order of genetic mutation occurrence from
somatic mutation cross-sectional data was formulated as
an Integer Linear Program (ILP) in [16]. Unlike existing
work, our approach neither correlates a single type of
cross-sectional data (e.g., mutation, gene expression, etc.)
with cancer prognosis, nor analyzes these different types
of data separately to combine the resulting analyses post-
factum. Instead we combine the information from somatic
mutations and gene expression data using mathematical
techniques and develop a model capable of inferring the
chronological sequence of alterations at the genome as
well as at the pathway level. Furthermore, our inference
model is not restricted to a priori defined cellular path-
ways, but is also able to identify such pathways and the
sequence in which these become altered during tumor
evolution.
Our work builds upon the formulation proposed in
[16] by first identifying the active cancer driver genes
(oncogenes and tumor suppressors) in the data set using
the approach from [17]. We address the issue of cancer
heterogeneity by using both somatic mutation and gene
expression data from cross-sectional measurements and
thus propose a newMixed Integer Linear Program (MILP)
formulation to model the molecular progression of can-
cer. Our formulation is based on the assumptions that
mutations accumulate over time [16, 18], and that differ-
ent mutations may cause similar changes in the cell’s state,
resulting in under/over expression of different groups of
genes. Moreover, we consider that the progression of the
disease is reflected in both the accumulation of muta-
tions and changes in gene expression levels. Finally, we
also assume that changes in gene expression may lead to
the appearance of new mutations. We validate the MILP
algorithm using simulated data and subsequently apply it
to real cross-sectional breast cancer data. As a result, we
are able to indentify phases of cancer progression that cor-
roborate known interactions between genes in important
Fleck et al. BMC Systems Biology  (2016) 10:12 Page 3 of 12
breast cancer pathways. Of note, we analyze breast cancer
data as a case study. However, our approach is general and
easily applicable to other types of cancer.
This paper is organized as follows. In section ‘Methods’
we outline the MILP formulation, describe how it can
be used to stratify molecular events such as mutation
and gene expression changes, and discuss the data sets
used in our analysis. Results obtained using both simu-
lated data and real breast cancer data are presented in
section ‘Results and discussion’. We conclude and discuss
future work in section ‘Conclusions’.
Methods
Modeling cancer progression using a mixed integer linear
program
The problem of partitioning mutational events into a tem-
poral sequence of events was formulated in [16] as an Inte-
ger Linear Program (ILP), in which an optimal partition
must satisfy two biologically meaningful requirements.
The first, termed exclusivity of mutations , derives from
the common assumption that at most one driver mutation
takes place during each step (or phase) of cancer progres-
sion. The second one establishes progression across phases
by enforcing that, for any given patient, a mutation in
some gene must take place in a given progression phase
in order for another gene to become mutated in a subse-
quent phase. The existence of passenger mutations, false
positives and false negatives inmutation detection, among
other factors, may lead to the violation of these require-
ments. Therefore, in order to enforce both exclusivity and
progression, changes may need to be made to the original
mutation data set.
In this paper paper we extend the model in [16] by
adding the interaction between somatic mutations and
gene expression. We propose a new Mixed Integer Linear
Program (MILP) formulation which identifies the order
in which mutations appear and produce changes of gene
expression. In our approach, a phase of cancer progres-
sion is defined by both a group of mutation genes and
a group of expression genes. We hypothesize that dur-
ing a cancer progression phase, certain mutations lead
to gene expression changes in multiple genes. More-
over, gene expression changes may cause mutations and
expression changes in the downstream cancer progres-
sion phases. Our formulation is based on the following
assumptions: (A1) Exclusivity of driver mutations within
each cancer progression phase.This implies that each sam-
ple can have only one mutated gene and each gene can
only be assigned to one phase; (A2) Progression of muta-
tions across subsequent phases, so that each sample must
have one gene mutated in the previous phase in order to
have a mutation in a subsequent phase; (A3) Causality
relationship between mutated genes and genes with abnor-
mal expression.Mutations in driver genes lead to changes
in expression of certain genes. Hence, if a sample has no
mutated genes in a given phase, all genes in the expression
subset of that phase must have normal expression; (A4)
The strength of the connection between expression and
mutation genes determines the assignment of the abnormal
expression genes to the corresponding phases. This means
that each expression gene is assigned to a certain phase
based on the strength of this gene’s connection to the
mutation genes that belong to that phase.
Our input data consists of an m × n binary mutation
matrix M, as well as an m × r expression matrix E, where
m is the number of samples (patients) in our database, n
is the number of mutation genes considered in our study,
and r is the number of expression genes considered in our




1 if mutation gene j is mutated in sample i
0 otherwise
while the entries Eih of the expression matrix correspond
to the measured expression level of expression gene h for
sample i. We define the connectivity between mutation
gene j and expression gene h to be the product between
the mutation status of gene j and the expression level of
gene h, compounded across all samples. Hence, we con-
struct an r×n real-valued connectivity matrixC ≡ ET ·M.
The value of entry Chj of the connectivity matrix can be
interpreted as follows: values closer to zero indicate that
most samples exhibit small absolute values of expression
levels for gene h and/or have no mutation in gene j; con-
versely, the further away the value of Chj is from zero, the
stronger is the connectivity between expression gene h
and mutation gene j across the data set.
It is thus clear that a stronger connectivity is obtained
when |Eih|  1m
m∑
i=1





of expression and mutation genes. Note that, in
what concerns the expression levels, this condition implies
that the most under/over expressed genes yield higher
connectivity scores. This in turn points to the relevance
of preprocessing matrix E so as to identify abnormally
low/high Eih values. Such task can be easily accomplished
through outlier detection techniques. While outliers are
typically associated with erroneous data, in this case val-
ues of Eih that deviate markedly from the mean expression
level are particularly relevant. Indeed, our ultimate goal
is to infer sequences of abnormal cellular behavior that
lead to cancer progression, which means that we are inter-
ested in analyzing genes that exhibit mutations and/or
abnormal expression levels. As a result, we performed a
percentile analysis for each expression gene h, h = 1, . . . , r
and considered entry Eih to be over (under, respectively)
expressed if it belonged to the 99th (1st , respectively)
percentile of gene h. As a final preprocessing step, we
Fleck et al. BMC Systems Biology  (2016) 10:12 Page 4 of 12
modified the values of all entries Eih so as to generate a
binary expression matrix, where the value of 1 indicated
that sample i belonged to either the 1st or 99th percentile
of gene h, and the value of zero indicated otherwise.
In this context, the problem of inferring a model of can-
cer progression can be cast as that of finding a partition
of the n columns of matrixM into K mutation phases and
a partition of the r columns of matrix E into K expres-
sion phases. We address the role of the number of phases
K in a subsequent discussion, but note that the value
of K is externally selected and varies depending on the
desired number of phases. Intuitively, K reflects the level
of abstraction of the model: a large (small, respectively)
value of K corresponds to a microscopic (macroscopic,
respectively) model. However, for the problem we con-
sider here, it is not reasonable to assume that a micro-
scopic model is necessarily superior to a macroscopic one,
hence the need to vary the value of K and scrutinize the
corresponding results. In this context, our problem can be












Mi,jpMj,k − aMi,k + 2f Mi,k
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k=1 pMj,k = 1 ∀ mutation gene j (C1)∑K
k=1 pEh,k ≥ 0 ∀ expression gene h (C2)∑n
j=1 pMj,k ≥ 1 ∀ phase k (C3)∑r
h=1 pEh,k ≥ 0 ∀ phase k (C4)
aMi,k ≥ aMi,k+1 ∀ sample i,∀ phase k (C5)
aMi,k ≤ f Mi,k +
∑n
j=1 Mi,j · pMj,k ∀ sample i,∀ phase k (C6)
pEh,k =
∑n
j=1 Ch,j · pMj,k ∀ expression gene h,∀ phase k (C7)
where the optimization is performed over variables pMj,k ,
f Mi,k , and aMi,k , which all take values in {0, 1} such that pMj,k =
1 if mutation gene j is assigned to phase Pk ; f Mi,k = 1 if we
need to flip one entry of columns in phase k in order for
phase k to be mutated in sample i; aMi,k = 1 if sample i
is considered mutated in phase k after any required flips.
We also optimize over variable pEh,k ∈ [0, 1], which is the
probability of expression gene h being assigned to phase k.
The objective function in (1) contains two terms, the
first of which was proposed in [16]. As mentioned pre-
viously, several factors may lead to the violation of con-
straints (C1)−(C6), whichmeans that it may be necessary
to alter the mutation matrix M by flipping some of its
entries from 0 to 1 (non-mutated to mutated) or 1 to 0
(mutated to non-mutated). In this context, the first term
of the objective function corresponds to the number of
entries of matrix M that need to be flipped, which should
be minimized. For the sake of completeness, we provide
here a brief interpretation of this term, and the reader is
referred to [16] for further details. For a given sample i,
i = 1, . . . ,m and phase k, k = 1, . . . ,K , once the values of
variables pMj,k , f Mi,k , and aMi,k have been fixed, the contribu-
tion of each sample i to the objective function corresponds
to the number of entries in phase k that are flipped in sam-
ple i. Since two types of flips are possible (i.e., f Mi,k = 1 if
either a 0 to 1 flip or a 1 to 0 flip is performed), this num-
ber is given by
∑n
j=1Mi,jpMj,k −aMi,k +2f Mi,k . The second term
of the objective function, which we seek to maximize,
compounds the probability of expression gene h being
assigned to phase k, for h = 1, . . . , r and k = 1, . . . ,K .
Note that because we define our objective function as
a combination of objectives, it is necessary to ensure that
each objective (i.e., each term of the objective function) is
properly normalized. For each term, a normalization fac-
tor was defined as an upper bound on the corresponding
objective component. It is simple to verify that, for the
first term, the upper bound on the number of flips that
could potentially need to be made corresponds to the total
number of elements in matrix M, which is given by the
product m · n. In the case of the second term, since pEh,k
is compounded across all expression genes and all phases,
the natural normalization factor is simply given by the
product r · K . Recall that we define variable pEh,k as the
probability of expression gene h being assigned to phase
k, so that it is also necessary to scale its value to the range
[0, 1]. From (C7), it can be seen that variable pEh,k is a com-
bination of matrix C and binary variable pMj,k . The latter is
naturally normalized, and the entriesChj of the former can




Additionally, it can be seen that (1) includes a weightW
associated with the second objective component. In order
to ensure that the objective function is a convex combi-
nation of objectives, we associate a weight 1 − W with
the first term. It is also important to mention that these
weights are not necessary for the purposes of normaliza-
tion, but that their values can be chosen so as to ultimately
reflect a desired trade-off (e.g., more importance can be
assigned to the mutation data by setting W < 0.5, and
vice-versa for the gene expression data).
Finally, we briefly discuss the interpretation of con-
straints (C1)−(C7). The first constraint ensures that each
mutation gene is assigned to exactly one cancer progres-
sion phase, while constraint (C2) enforces the assignment
of each expression gene to at least one cancer progres-
sion phase. Moreover, any phase must consist of at least
one mutated gene, but may have no expression genes
assigned to it (constraints (C3) and (C4), respectively).
Progression of mutational events is ensured in the fifth
constraint, whereby sample imust have a certain mutated
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gene assigned to phase k, in order for this same sample to
have another mutated gene assigned to phase k + 1. Con-
straint (C6) simply enforces the fact that, if sample i has a
given mutated gene j assigned to phase k, then this gene is
either already mutated in the original mutation matrixM,
or its mutation status is a result of a 0 → 1 mutation flip.
The last constraint ensures that the assignment of each
expression gene h to any phase k is determined in terms of
the corresponding probability pEh,k .
We end by noting that, while exclusivity of driver muta-
tions within each cancer progression phase is enforced in
our formulation, exclusivity of changes in expression lev-
els is not. As a result, for any given sample i, more than
one expression gene h may be assigned to phase k. Nev-
ertheless, our formulation enforces a temporal association
between mutational events and changes in gene expres-
sion. In other words, for any given sample i, no expression
genes may be assigned to phase k, unless a given mutation
gene j has been assigned to this phase. For illustrative pur-
poses, an example of a feasible solution for the proposed
MILP is presented in Fig. 1.
Data
We test the approach by using both simulated data and
real cancer data. We apply our model on the breast inva-
sive carcinoma (BRCA) data set generated by the The
Cancer Genome Atlas (TCGA) Research Network. Pub-
licly available somatic mutation data (level 2) and gene
expression data (level 3) was downloaded from TCGA
[19]. The somatic mutations data was profiled for 993 sub-
jects by Whole-Exome Sequencing on Illumina GA DNA
Sequencing platform. Gene expression generated on UNC
Agilent G4502A was profiled for 547 subjects [1]. For our
analysis, we consider 529 subjects with both types of data
measurements (somatic mutations and gene expression).
Our approach is general and we can infer the sequence
of events for any gene sets. However, in this paper we
consider genes that are more relevant to breast cancer.
To select the relevant cancer driver genes based on their
mutation frequency we use the 20/20 rule proposed in
[17] which classifies genes into oncogenes or tumor sup-
pressors.
Results and discussion
In what follows we present the results obtained by apply-
ing our methodology to both simulated data and real
patient data from breast cancer studies. In all cases the
MILP was solved using CPLEX v12.6 with default param-
eters.
Simulated data
We performed an experiment using simulated data to
illustrate the desired behavior of our model. For such, we
used an m × n binary simulated mutation matrix MS and
an r × n real-valued simulated connectivity matrix CS,
where m is the number of samples in our data set, n is
the number of mutation genes, and r is the number of
expression genes. For simplicity, and without loss of gen-
erality, we take MS to be the mutation matrix obtained
from the TCGA breast cancer data set, where m = 529
samples and n = 72 mutation genes (as described in
section ‘TCGA breast cancer data’). The purpose of our
simulation experiments is to show that our MILP model
is capable of correctly extracting the information con-
tained in mutation and gene expression data regarding
which expression genes are more strongly connected to
which mutation genes. Hence, we arbitrarily assigned val-




for h = 1, . . . , r. This condition enforces an extreme sce-
nario in which each expression gene is only connected to
a single mutation gene. Thus, the expected outcome of
applying ourMILPmodel to such data is that each expres-
sion gene should be uniquely assigned to the same phase
as the mutation gene to which it is connected. For simplic-
ity, and also without loss of generality, we took r = 319
expression genes, so as to make the dimensions of the
simulated data compatible with those of the real data we
analyze.
Three simulation runs were performed by varying the
number of phases K such that K ∈ {2, 3, 4}, and the
corresponding results are shown in Tables 1, 2, 3. In all
cases, our results showed that expression genes were par-
titioned in complete agreement with the connectivity data
contained in CS. In other words, each expression gene h,
Fig. 1 Example of a feasible solution of the MILP formulation proposed in this paper. Red boxes represent genes with mutation. Orange boxes mark
genes with altered gene expression levels. White boxes correspond to those entries with no mutations or no expression changes
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Table 1 Number of mutation and expression genes assigned to
each phase of cancer progression using simulated data for K=2




The total number of genes is highlighted in bold
h = 1, . . . , r, was assigned to phase k, k = 1, . . . ,K , iff
cShj = 1 andmutation gene j, j = 1, . . . , n, was also assigned
to phase k. For example, by analyzing Table 3 and the data
in matrix CS, it is possible to verify that the 101 expres-
sion genes in phase k = 1 are precisely the same ones that
are connected to the mutation genes assigned to phase 1
(a similar analysis also holds for phases k = 2, 3, 4).
TCGA breast cancer data
Selecting relevant cancer genes
In order to determine the sequence of somatic mutation
and gene expression changes, we first narrow down the
mutation and expression gene sets to interesting breast
cancer genes. In [16] the authors consider all present
mutations. However, since many somatic mutations are
passenger and do not impact cancer progression, we first
select those genes that are more likely to be drivers. More-
over, some genes are known to be involved in cancer
associated cell processes, such as proliferation, migration
and apoptosis. We are interested to see how the expres-
sion of these genes is affected by the driver mutation and
which is the temporal order of changes that occur during
cancer progression.
To select the relevant cancer driver genes based on their
mutation frequency, we first classify genes into oncogenes
or tumor suppressors by using the 20/20 rule [17]. This
method takes into account particular types of mutations
and their frequencies. First, for a given gene, the total
number of variants is computed across the data set. Then,
each gene is assigned an oncogene (ONG) score and a
tumor suppressor gene (TSG) score which are computed
based on the frequency of gain-of-function or loss-of-
function mutations, respectively. Gain-of-function muta-
tions are defined as missense or in-frame indels that
are recurrently mutated at the same aminoacid position,
Table 2 Number of mutation and expression genes assigned to
each phase of cancer progression using simulated data for K=3





The total number of genes is highlighted in bold
Table 3 Number of mutation and expression genes assigned to
each phase of cancer progression using simulated data for K=4






The total number of genes is highlighted in bold
while loss-of-function mutations are nonstop, nonsense
and frameshift indels [17]. For each gene, the ONG score
is the frequency of gain-of-function mutations out of the
total number of variants, while the TSG score is the fre-
quency of all loss-of-function mutations out of the total
number of variants. If the ONG score is greater than 20%,
then the gene is classified as an oncogene. Similarly, if the
TSG score is higher than 20%, then the gene is classified
as a tumor suppressor.
We consider a gene to be a potential cancer driver if it
presents mutations across the data set (a minimum num-
ber of 20) and has an ONG or a TSG score greater than
20%. Based on this criterion, 72 genes are selected. The
list of 72 genes include genes that were previously found
to be highly mutated in breast cancer, such as: PIK3CA,
PTEN, TP53, GATA3, CDH1, RB1, MLL3, MAP3K1,
TBX3, RUNX1, CBFB, NF1 [1] .
To infer the cancer progression phases of gene expres-
sion changes we consider the Pathways in Cancer set from
the Kyoto Encyclopedia of Genes and Genomes database
(KEGG) [20, 21]. After overlapping this set with our data,
we obtain 319 genes which are known to play a role in
cancer initiation and progression.
Therefore, we consider two sets of genes: genes that
present driver mutations and genes implicated in cancer
development.
Finally, we wish to infer the stages in which mutations
occur and the relations between mutational events and
gene expression changes. For this, we apply the proposed
MILP model as detailed next.
Identifying a temporal sequence ofmutation events and gene
expression changes for breast cancer
We applied the proposed MILP formulation with a dif-
ferent number of predefined phases K = 2, 3, 4, 5 and
selected the most biologically meaningful one. For a num-
ber of 3 phases, the algorithm was able to stratify the
mutation and expression genes in different proportions
within each phase. For K = 2, 4, 5, most of the expres-
sion genes were placed in one phase and the results
do not reflect a gradual progression. Figures 3(a), (b),
4(a), (b), 5(a), (b), and 6(a), (b) illustrate the number
of genes assigned to each phase for the expression and
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mutation groups. For a number of 3 phases, the muta-
tion genes are more or less evenly distributed across the
3 phases (Fig. 4(a)). The mutation genes of each phase
are shown in Fig. 2. In addition, one can notice that
the number of gene expression modifications gradually
decrease from phase 1 to phase 3 (Fig. 4(b)). As expected,
more cancer genes present abnormal expression under
the influence of earlier stage mutations, such as PIK3CA
and PTEN, since these genes are important in cancer
initiation.
The proposed 3-phase sequence of events in breast
cancer, for the two sets of 72 mutation genes and 319
expression genes can be found in Additional file 1.
Furthermore, we validate our results by running sim-
ilar experiments of different number of phases, on the
same number of arbitrarily selected genes, both for muta-
tion and expression sets (Figs. 3(c), (d), 4(c), (d), 5(c), (d),
and 6(c), (d)). By randomly selecting these genes from the
entire data set of 17814 genes, not all of them will partic-
ularly be associated with cancer events. Therefore, these
experiments will serve as a negative control. As expected,
in all of the experiments we ran on the randomly selected
genes, the MILP assigns most of the genes to one phase,
not being able to find a temporal sequence of events. In
addition, 20% of the expression genes are not assigned
to any phase. Figures 4(c) and 4(d) illustrate the random
results for K = 3 phases using random gene sets. One can
notice the difference between the progression of cancer
genes compared to random genes.
The idea of comparing the results generated on the
genes of interest with those on a randomly selected set
of genes could serve as a general approach for select-
ing K. The adequate value for K will most likely change
when different cancer data sets or gene sets are used.
Therefore, it is important to select the best configura-
tion as the one that gives the most biological meaningful
Fig. 2 Optimal solution of the MILP algorithm for cancer mutation and expression genes (K=3). Shown here is the assignment of mutation genes to
each phase of cancer progression
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a b
c d
Fig. 3 Number of genes assigned to each phase of cancer progression
for K = 2 (a) cancer mutation genes; (b) cancer expression genes; (c)
randommutation genes; (d) random expression genes: 20% of genes
were not assigned to any phase
results and that also differs from the negative control.
This approach for selecting K can generally be applied
to any cancer data set, as long as it is also com-
bined with biological insight about the analyzed set of
genes.
For any given phase of mutation and expression genes,
a patient has one and only one mutated gene during each
phase which is associated to one or more genes with
abnormal gene expression level. Therefore, our method
is able to stratify the heterogeneity of mutations and
gene expression changes into a temporal order of events.
This crucial observation points to the contribution of this
work, but it also brings to light the issue of uniqueness
of solution of the proposed MILP formulation, which we
briefly address here. Note that the existence of a single
optimal solution to our problem indicates that it is possi-
ble to find a unique configuration of phases that optimally
satisfies our formulation. On the other hand, the lack of
a unique optimum means that several equivalent solu-
tions could potentially be identified, and that different
configurations of phases could yield similar results. More
a b
c d
Fig. 4 Number of genes assigned to each phase of cancer progression
for K = 3 (a) cancer mutation genes; (b) cancer expression genes; (c)
randommutation genes; (d) random expression genes: 20% of genes
were not assigned to any phase
importantly, either scenario (unique or multiple optimal
solutions) may bring new insights for understanding the
mechanisms of cancer development. In what follows, we
present the insights provided by the results reported in
this work.
We begin by evaluating the proposed partition so as
to identify known causal gene relationships from can-
cer pathways, such as PI3K/AKT and TP53 from KEGG
[21]. Figure 7(a) shows such interactions which occur in
phase 1. PIK3CA is an oncogenic driver which is highly
mutated in breast cancer (the ONG score computed based
on the method in [17] is 90% compared to a TSG score
of 0.5%). Also, PTEN gene presents significant loss-of-
function mutations (the TSG score is 51% compared to an
ONG score of 5%). We find PIK3CA and PTEN as being
mutated in early stage during phase 1. Also, the events
in phase 1 produce abnormal gene expression changes of
TP53. TP53 is a well known tumor suppressor [22–24],
situated downstream PIK3CA and PTEN in PI3K/AKT
pathway. Mutations in PIK3CA or PTEN genes may
decrease the gene expression level of TP53 tumor
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Fig. 5 Number of genes assigned to each phase of cancer progression for K = 4 (a) cancer mutation genes; (b) cancer expression genes; (c) random
mutation genes; (d) random expression genes: 20% of genes were not assigned to any phase
suppressor through AKT/MDM2 cascade. Consequently,
low expression of TP53may induce cell survival (Fig. 7(a)).
Next, we evaluate the number of patients that present
a potentially active PI3K/AKT pathway. We find 20%
of patients to have mutations in PIK3CA, as well as
decreased TP53 expression. In addition, about 2% of
patients present PTEN mutations, as well as decreased
TP53 expression (Fig. 7(a)). In order to estimate if a gene
is over- or under-expressed we compared the log nor-
malized gene expression to 0 (negative values indicate
under-expression in respect to the normal level, while
positive values indicate over-expression in respect to the
normal level).
Moreover, we identify changes in TP53 pathway during
phase 2 of progression, as shown in Fig. 7(b). Mutations
in TP53 gene generally produce the loss-of-function of
its tumor suppressor activity [23]. Loss-of-function of
TP53 gene may cause abnormal gene expression levels of
the downstream genes, such as PTEN and IGF-1, which
may activate the IGF1-mTOR cellular growth pathway
and inhibit apoptosis. As expected PTEN and IGF-1 are
assigned to phase 2 expression genes of the proposed
3-phase partition.
We find 29% of patients to have amutation in TP53 gene
and increased IGF-1 expression. Moreover, 6% of patients
present a TP53 mutation, as well as both increased
IGF-1 expression and decreased PTEN expression
(Fig. 7(b)).
Interestingly, about 5% of patients present mechanisms
of both PI3K/AKT and TP53 pathways. They have a
mutation in PIK3CA gene and decreased TP53 expres-
sion (Fig. 7(a)). In addition, they present mutations in
TP53 gene and increased IGF-1 expression (Fig. 7(b)).
Based on our approach, we are able to infer that muta-
tions in PIK3CA (phase 1) precede the mutations in TP53
(phase 2).
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Fig. 6 Number of genes assigned to each phase of cancer progression for K = 5 (a) cancer mutation genes; (b) cancer expression genes; (c) random
mutation genes; (d) random expression genes: 20% of genes were not assigned to any phase
Conclusions
In this paper we propose a novel approach of integrating
somatic mutations with gene expression data to infer the
temporal sequence of mutation events and gene expres-
sion changes during cancer progression.
First, we validate the model using simulated data. Sec-
ond, we apply the approach on breast cancer data from
TCGA. We identify the temporal order of molecular
changes of 72 most highly mutated driver genes in breast
cancer data set and 319 cancer associated genes from
KEGG Pathways in Cancer gene set. Moreover, we iden-
tify known gene relationships from PI3K/AKT and TP53
pathways.
Our approach is general and can be applied to other
sets of genes of interest, as well as to other types of
cancer. Larger sets of genes that potentially play a role
in cancer progression can be analyzed. The temporal
sequence of events also illustrates the causal relationships
between potential mutation events which occur during
a phase and the consequent expression changes dur-
ing that phase. This information could be used for
developing efficient drug combinations which target a
specific group of genes that cause important expres-
sion changes. As future work we plan to further eval-
uate the method in other cancer data sets that provide
somatic mutations and gene expression measurements
of the same patients, such as TCGA colorectal cancer,
glioblastoma, lung squamous cell carcinoma and ovarian
cancer.
Our model identifies the groups of genes which change
during cancer progression from cross-sectional data.
Moreover, it offers new insights for understanding the het-
erogeneity of cancer mechanisms which are reflected by
different combinations of mutations and gene expression
changes. Our framework can be used to further address
clinical questions and improve therapeutic strategies, such
as the development of early detection biomarkers and
efficient drug combinations.
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a
b
Fig. 7MILP model identifies causal relationships from PI3K/AKT and
TP53 pathways (KEGG) (a) PI3K/AKT pathway is altered in phase 1 of
breast cancer progression; (b) TP53 pathway is altered in phase 2 of
breast cancer progression
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